SEPRA Trademark

Trademark Overview

On Thursday, June 15, 2000, a trademark application was filed for SEPRA with the United States Patent and Trademark Office. The USPTO has given the SEPRA trademark a serial number of 76070905. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, September 22, 2023. This trademark is owned by Genzyme Corporation. The SEPRA trademark is filed in the Medical Instrument Products category with the following description:

Medical devices, namely, biopolymers in the forms of films, gels, mesh and coatings for use in cardiovascular, neurological, abdominal, pelvic and nasal surgical procedures to reduce or prevent adhesions
sepra

General Information

Serial Number76070905
Word MarkSEPRA
Filing DateThursday, June 15, 2000
Status710 - CANCELLED - SECTION 8
Status DateFriday, September 22, 2023
Registration Number2694482
Registration DateTuesday, March 11, 2003
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, December 17, 2002

Trademark Statements

Pseudo MarkSEPRA
Goods and ServicesMedical devices, namely, biopolymers in the forms of films, gels, mesh and coatings for use in cardiovascular, neurological, abdominal, pelvic and nasal surgical procedures to reduce or prevent adhesions

Classification Information

International Class010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials.
US Class Codes026, 039, 044
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, September 22, 2023
Primary Code010
First Use Anywhere DateSunday, October 1, 1995
First Use In Commerce DateSunday, October 1, 1995

Trademark Owner History

Party NameGenzyme Corporation
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142
Party NameGenzyme Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressFramingham, MA 017019322
Party NameGenzyme Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressFramingham, MA 017019322

Trademark Events

Event DateEvent Description
Friday, September 22, 2023CANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9
Friday, March 11, 2022COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Wednesday, January 8, 2020REVIEW OF CORRESPONDENCE COMPLETE - ADDRESS UPDATED
Tuesday, December 10, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, April 12, 2019APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, April 12, 2019TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, April 12, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, April 12, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, February 27, 2013NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Wednesday, February 27, 2013REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Wednesday, February 27, 2013REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Wednesday, February 27, 2013CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Tuesday, February 12, 2013TEAS SECTION 8 & 9 RECEIVED
Tuesday, February 12, 2013TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, May 6, 2008REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Monday, May 5, 2008ASSIGNED TO PARALEGAL
Thursday, April 17, 2008TEAS SECTION 8 & 15 RECEIVED
Friday, January 4, 2008CASE FILE IN TICRS
Tuesday, March 11, 2003REGISTERED-PRINCIPAL REGISTER
Tuesday, December 17, 2002PUBLISHED FOR OPPOSITION
Wednesday, November 27, 2002NOTICE OF PUBLICATION
Monday, April 8, 2002APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, January 25, 2002CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, October 24, 2001FINAL REFUSAL MAILED
Thursday, October 18, 2001ASSIGNED TO EXAMINER
Thursday, April 19, 2001CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, November 17, 2000NON-FINAL ACTION MAILED
Tuesday, November 14, 2000ASSIGNED TO EXAMINER
Thursday, November 9, 2000ASSIGNED TO EXAMINER

Related Keywords

sepra nasal pelvic abdominal surgical procedures adhesions prevent reduce neurological cardiovascular